lestaurtinib has been researched along with Prostatic Neoplasms in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Attwood, K; Azabdaftari, G; Ben-Salem, S; Cortes, E; Dehm, SM; DePriest, AD; Heemers, HV; Hu, Q; Jamieson, C; Klein, E; Kumari, S; Liu, S; Magi-Galluzzi, C; Mohler, JL; Mudduluru, G; Pop, E; Senapati, D; Shah, RB; Sharifi, N; Su, Y; Venkadakrishnan, VB | 1 |
| Bologna, M; Dolo, V; Festuccia, C; Ficorella, C; Gravina, GL; Millimaggi, D; Muzi, P; Ricevuto, E; Vicentini, C | 1 |
| Eberlin, A; Erlenkamp, G; Jung, M; Köhler, J; Metzger, E; Rumpf, T; Schüle, R; Sippl, W; Slynko, I | 1 |
| Beckhardt, S | 1 |
| Bologna, M; Dolo, V; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Ricevuto, E; Speca, S; Vicentini, C | 1 |
| Bologna, M; Festuccia, C; Gravina, GL; Muzi, P; Pomante, R; Ricevuto, E; Ventura, L; Vicentini, C | 1 |
| Carducci, MA; Collins, C; Denmeade, SR; Eisenberger, MA; Isaacs, JT; Partin, AW; Pili, R; Sinibaldi, VJ; Walczak, JS | 1 |
| Angeles, T; Dionne, CA; George, DJ; Isaacs, JT; Jani, J; Lamb, J; Murakata, C | 1 |
| Dalrymple, SL; Denmeade, SR; Dionne, CA; Isaacs, JT; Lamb, JC; Miknyoczki, S; Weeraratna, AT | 1 |
9 other study(ies) available for lestaurtinib and Prostatic Neoplasms
| Article | Year |
|---|---|
Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy.
Topics: Androgens; Animals; Carbazoles; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Furans; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Prostatic Neoplasms; Protein Kinase C; Sequence Analysis, RNA; Serum Response Factor; Transcription Factors | 2019 |
Her2 crosstalks with TrkA in a subset of prostate cancer cells: rationale for a guided dual treatment.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carbazoles; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Furans; Male; Mice; Nerve Growth Factor; Prostatic Neoplasms; Receptor Cross-Talk; Receptor, ErbB-2; Receptor, trkA; Receptors, Androgen; Xenograft Model Antitumor Assays | 2009 |
Lestaurtinib inhibits histone phosphorylation and androgen-dependent gene expression in prostate cancer cells.
Topics: Androgens; Carbazoles; Cell Line, Tumor; Cells, Cultured; Enzyme Inhibitors; Furans; Gene Expression; Histones; Humans; Male; Phosphorylation; Prostatic Neoplasms; Protein Kinase C; Receptors, Androgen | 2012 |
Re: growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer therapy.
Topics: Carbazoles; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Furans; Humans; Indoles; Male; Prodrugs; Prostatic Neoplasms; Protein-Tyrosine Kinases | 2004 |
Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro.
Topics: Brain-Derived Neurotrophic Factor; Carbazoles; Cell Line, Tumor; Enzyme Inhibitors; Furans; Humans; Indoles; Male; Neoplasm Invasiveness; Nerve Growth Factors; Prostatic Neoplasms; Protein-Tyrosine Kinases; Receptor, trkA; Receptors, Androgen | 2007 |
In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma.
Topics: Adult; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Blotting, Western; Carbazoles; Carcinoma; Cell Line, Tumor; Cohort Studies; Dihydrotestosterone; Furans; Humans; Immunohistochemistry; Indoles; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Protein Kinase Inhibitors; Receptor, Nerve Growth Factor; Receptor, trkA; Receptor, trkC; Tosyl Compounds | 2007 |
Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint.
Topics: 3T3 Cells; Aged; Aged, 80 and over; Animals; Carbazoles; Cell Line, Tumor; Drug Screening Assays, Antitumor; Furans; Humans; Indoles; Male; Mice; Mice, Nude; Middle Aged; Neoplasm Metastasis; Neoplasm Transplantation; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors | 2007 |
Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
Topics: Adenocarcinoma; Administration, Oral; Androgens; Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Carbazoles; Combined Modality Therapy; Drug Screening Assays, Antitumor; Drug Synergism; Furans; Indoles; Injections, Subcutaneous; Leuprolide; Male; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Proto-Oncogene Proteins; Rats; Receptor Protein-Tyrosine Kinases; Receptor, trkA; Receptors, Nerve Growth Factor | 1999 |
Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Carbazoles; Cell Division; Cell Line; Disease Models, Animal; Furans; Humans; Indoles; Male; Mice; Mice, Nude; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Rats; Receptor, trkA; Survival Analysis; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |